Status:

UNKNOWN

Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors

Lead Sponsor:

Institute of Cancer Research, United Kingdom

Conditions:

Head and Neck Cancer

Ototoxicity

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause...

Detailed Description

OBJECTIVES: Primary * To determine the potential of cochlear-sparing intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy comprising 3-dimensional conformal radiotherapy in reduc...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically confirmed malignant tumors of the parotid glands
  • Adjuvant radiotherapy planned post-surgery
  • No parotid tumors requiring primary radiotherapy
  • No benign tumors requiring postoperative radiotherapy
  • No metastases from squamous cell carcinoma of the head and neck to the parotid gland
  • At high-risk of radiation-induced sensory-neural hearing loss with conventional radiotherapy due to the irradiation of the parotid bed to a dose equivalent of 60 Gy in 2 Gy/fraction with photon beams, using the wedge-pair technique
  • PATIENT CHARACTERISTICS:
  • WHO performance status 0-1
  • No hearing loss \> 60 dB
  • No previous or concurrent illness that, in the investigator's opinion, would interfere with either completion of therapy or follow-up
  • Suitable to attend regular follow-up and undergo audiograms and toxicity monitoring and be available for long term follow-up
  • PRIOR CONCURRENT THERAPY:
  • See Disease Characteristics
  • No prior radiotherapy to the head and neck region
  • No concurrent chemotherapy

Exclusion

    Key Trial Info

    Start Date :

    August 1 2008

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    Estimated Enrollment :

    84 Patients enrolled

    Trial Details

    Trial ID

    NCT01216800

    Start Date

    August 1 2008

    Last Update

    October 7 2010

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Royal Marsden - London

    London, England, United Kingdom, SW3 6JJ